Device automation for rapid tissue sizing to support breast cancer care
Official title: Device Automation of an FDA-cleared CD-Microfluidic Platform for Rapid Tissue Microsizing
Funded at Syntr Health Technologies, LLC · NIH-11421478 · Data updated 2026-11-12
A new FDA-cleared device platform aims to automate tissue processing and small-tissue sizing to help researchers study breast cancer more efficiently and to support potential patient treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Syntr Health Technologies, LLC NIH-funded |
| Lab location | 1 site (Irvine, UNITED STATES) |
| Project start | September 25, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,000,251 |
| NIH project number | 5R44TR004975-03 |
| Project ID | NIH-11421478 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with breast cancer or related tissue conditions who may benefit from improved tissue processing or autologous adipose tissue–based therapies.
✕Less likely to help
Patients not undergoing breast cancer surgery or reconstruction may not directly benefit from these tissue-processing advancements.
What this research studies
This project centers on expanding an automated tissue processing platform that dissociates tumor tissue into single cells for analysis, with applications in breast cancer. It highlights using autologous adipose tissue microsizing for potential reinjection to aid healing and reconstruction. The work builds on prior human and animal data showing promising tissue processing and a move toward clinical use. By improving throughput and consistency, the platform could enhance understanding of tumor heterogeneity and enable faster translation to patient care. The grant emphasizes real-world potential in cancer treatment and reconstruction through streamlined tissue processing.
Why it matters
Potential benefit: If successful, patients could benefit from faster, more precise tissue analysis and improved options for autologous tissue use in reconstruction and healing.
How similar studies have gone: Preliminary human data show favorable wound closure with autologous tissue processed on the platform, suggesting potential for clinical impact.
Where this research is happening
-
Syntr Health Technologies, LLC
Irvine, United States Active
Researchers
- Principal investigator: Zobi, Ahmed Nabil — Syntr Health Technologies, LLC
- Study coordinator: Zobi, Ahmed Nabil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.